Some biologic drugs increase risk for serious infection

| Melissa Leavitt

Some biologic drugs may increase your risk for serious infections, according to the results of a study published in May in the journalJAMA Dermatology.

The study found that taking Remicade (infliximab) or Humira (adalimumab) may put you at a higher risk for serious infections than non-biologic drugs. However, the same study found that Stelara (ustekinumab) and Enbrel (etanercept) do not appear to be associated with a serious infection risk, according to the findings.

Researchers used a large database containing information about psoriasis patients, known as the PSOLAR registry, to search for any connection between biologics and serious infections. Biologics included in the study were Enbrel, Humira, Remicade and Stelara. The list of non-biologic treatments researchers analyzed included methotrexate, systemic retinoids and phototherapy.

Infections were considered serious if they were life-threatening or led to disability, hospitalization or some other medical condition, the researchers noted. The most common serious infections occurring in the study were pneumonia and cellulitis, a bacterial skin infection, according to the findings.

More than 11,000 psoriasis patients were included in the study. Of these, more than 9,000 were on biologics, 490 were on methotrexate and 1,610 were taking other treatments, according to the findings.

According to the results, the risk of developing a serious infection more than doubled for patients on Remicade or Humira, compared with patients not taking a biologic. Taking Stelara or Enbrel was not associated with risk for a serious infection, researchers found.

The results are in line with other studies that found a connection between a risk of serious infection and a type of biologic known as a tumor necrosis factor-alpha (TNF-alpha) inhibitor, the researchers noted. Both Humira and Remicade are TNF-alpha inhibitors. Enbel also targets TNF-alpha, but in a different way from Humira and Remicade, according to the researchers.

Stelara does not target TNF-alpha, but instead targets two different pro-inflammatory proteins, or cytokines, known as interleukin 12 and interleukin 23.

The study was funded by Janssen, the company that makes Stelara. 

Driving discovery, creating community

For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.

Recent Advance Posts

Capitol hill, advocacy, legislation
We will continue to advocate for better health care for psoriatic disease...
LITE study logo
A new clinical trial researching the effectiveness and safety of home-based...
cartoon of people studying giant book
NPF and the American College of Rheumatology release a pioneering treatment...
Psoriatic disease patient Ellen Clements
Ellen Clements overcomes flares, joint pain and bullies in the office to...
Michael Bentley on his radio
A Texas man finds the right specialists and gets approved for disability...
Leah McCormick Howard and Stephen Katz
Longtime NIAMS director was a friend to all he served.
cartoon two scientists with giant microscope and helix in background
You don’t need an advanced degree in biochemistry to be a Citizen Pscientist,...
Edgar Payano, psoriasis, Dominican
A Dominican-American man with psoriasis fends off the usual annoying questions...
NPF, Tide, Seal of Recognition, Proctor & Gamble
NPF awards Seal of Recognition to two Procter & Gamble Tide products.